Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07456696 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
A Phase 3 study of Post Traumatic Stress Disorder, sponsored by Transcend Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 3
- Study locations
NCT07456696: Recruiting Phase 3 study of Post Traumatic Stress Disorder, sponsored by Transcend Therapeutics.
NCT07456696 is a Phase 3 study of Post Traumatic Stress Disorder that is actively recruiting participants, run by Transcend Therapeutics. The registered enrollment target is 300 participants, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (55% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07456696, a Phase 3 study of Post Traumatic Stress Disorder, is actively recruiting participants, sponsored by Transcend Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
Primary Outcome
CAPS-5 is a structured interview designed to assess PTSD symptoms severity. The total severity score ranges from 0 to 80, with a higher score indicating more severe symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TSND-201
Study Locations (3)
Florida
- CNS Healthcare - Jacksonville
- CNS Healthcare - Orlando
Arkansas
- Preferred Research Partners - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What NCT07456696 shows while recruiting
NCT07456696 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07456696 reports a single indexed study location in Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT07456696 about?
NCT07456696 is a clinical study titled "An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)". This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter...
What is the current status of trial NCT07456696?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-03. Estimated completion is 2027-12.
What conditions does trial NCT07456696 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT07456696?
The interventions under investigation include: Placebo (DRUG), TSND-201 (DRUG).
Who is sponsoring clinical trial NCT07456696?
This trial is sponsored by Transcend Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07456696 being conducted?
This trial has 3 study locations across Arkansas, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07456696's enrollment target sits among peer trials
300 28th of 262 higher than 230 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
RECRUITING · Phase 3
-
MDMA-assisted Massed Prolonged Exposure for PTSD
RECRUITING · Phase 3
-
Repurposing Low-Dose Clonidine for PTSD in Veterans
RECRUITING · Phase 3
-
Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests
ACTIVE NOT RECRUITING · Phase 3
-
Frontline Clinician Psilocybin Study
COMPLETED · Phase 3
-
Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia